Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions.
- Share Price (Ordinary): £12.97
- Share Price (ADR): $41.19
- Dividend Date: October 7, 2010
Material Changes
On October 12, 2010, the Administrators of the Performance Share Plan notified the Company of an increase in notional interests for various participants. This increase resulted from the notional re-investment of the dividend paid on October 7, 2010. The filing lists specific share and ADR increases for 17 individuals, including Mr. A P Witty (14,298.42 Ordinary shares) and Mr. J S Heslop (5,808.21 Ordinary shares).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Investor Verification Checklist
- Verify the vesting schedule and conditions for the GlaxoSmithKline Performance Share Plan to understand future payout obligations.
- Confirm the total number of shares and ADRs held by directors and connected persons following this re-investment.
- Review the company's broader financial reports (e.g., Form 20-F) for actual revenue and profit data, as this filing does not contain them.